#3104 Adequacy of nephroprotective prescription in an elderly diabetic population in a primary care setting

Abstract

Abstract Background and Aims The prevalence of chronic kidney disease (CKD) has been increasing and one of the main risk factors is diabetes mellitus (DM). The addition of sodium-glucose cotransporter 2 inhibitors (SGLT2i) to the renin-angiotensin inhibitors (RASi) is recommended in patients with DM and CKD due to the benefits in metabolic control, decrease in proteinuria, and in delaying glomerular filtration decline. Method A retrospective cohort was performed and included a sample of patients with diabetes registered and monitored in a primary care facility. A random sample was selected, calculated for an expected prevalence of 40%, error of 4%, and alpha of 0.05. The primary outcome was to assess the adequacy of nephroprotective prescription. Secondary outcomes were to determine the prevalence of CKD (and associated factors) in the sample, and to assess the percentage of patients with correct CKD diagnosis. Demographic and analytical data of patients (glomerular filtration rates and values of albuminuria) were collected from their electronic health records. Statistical analysis was performed using SPSS v28.0. A p-value < 0.05 was considered statistically significant. The study protocol was approved by the Ethics Committee. Results 338 patients were included, 58% were men, and with a mean age of 71.4 years. 22.2% [95% CI 16.2-29.7%] of patients had the pathology properly coded in the problem list. The prevalence of CKD found was 42.6% [95% CI 37.4-48.0%]. Most patients were in stages G2 (33.3%), G3a (30.6%) and G3b (14.6%). Concerning albuminuria, most were in stage A2 (68.8%). Of the patients with CKD, 77.1% [95% CI 69.6%-83.2%], 60.4% [95% CI 52.3%-68.0%] and 43.1 [95% CI 35.3–51.2%] were medicated with RASi, SGLT2i and both, respectively. Conclusion In this primary setting study, the majority of this elderly population was under nephroprotective therapies (RASi and/or SGLT2i). The relatively low coding suggests underdiagnosis. Further optimization of nephroprotective therapies can be made in order to avoid renal failure, as long as the pathology is properly recognized.